Alloksys’s Academic and Institutional Platform
The network of collaborations with Dutch Academic and Clinical Research groups is a key element of the strategy of Alloksys. The role of Alloksys is primarily in managing these collaborations, and coordinating the efforts of each of the partners. In these collaborations Alloksys get access to the knowledge and experience of the different partners and initiates and combines the efforts in the drug development process.
University of Utrecht
Alloksys uses laboratory facilities at the IRAS (Institute of Risk Assessment Sciences) located at the Faculty of Veterinary Sciences of Utrecht University.
Through IRAS, Alloksys has access to unparalleled GLP-facilities to perform studies at the General Animal Facility (Gemeenschapelijk Dierexperimenteel Laboratorium [GDL]) of Utrecht University, in a wide array of animal models, e.g. in pigs, rats and mice.
University of Wageningen/Plant Research International
Feasibility studies are carried out in the expression of different phosphatases in solanaceae. These recombinant alkaline phosphatases may foster future programs (not disclosed here)
University of Utrecht. And other national and international partners: Immunath EU FW6 program
EuroTransBio (ETB) program THERAPTECH : objective; development of recombinant alkaline phosphatase compatible with chronic disease management. An Euro Trans Bio subsidy has been granted to this challenging project. The initiation of this project was in Q1 of 2009. partners here are CEVEC (Cologne, Germany) and IBET (Oeiras, Portugal)
Clinical programs planned on complicated cardiac surgery, variceal bleeding, solid organ transplant, rheumatoid arhritis at several medical centers in the USA, UK and the Netherlands |
| 
Press releases
|
24 nov 2011: Hoopgevend onderzoek aan veelzijdig nieuw type geneesmiddel |
| Onderzoeksresultaten ondersteunen de theorie dat diverse aandoeningen
kunnen worden bestreden of voorkomen door toediening van bepaalde, van nature in het lichaam voorkomende, enzymen. Deze aandoeningen betreffen met name ontstekingsreacties en deze onde... |
| Read more.. |
|
Alloksys Life Sciences announces positive results with alkaline phosphatase in a phase IIa Clinical Trial in Patients undergoing CABG surgery with CPB. |
| Bunnik, The Netherlands, 23 April 2008 - Dutch biotechnology company Alloksys Life Sciences announces the successful completion of a phase IIa clinical trial (APPIRED) in patients undergoing bypass surgery with cardiopulmonary bypass... |
| Read more.. |
|
Drug development program started based on CAP Human Cell Line. New platform may provide solutions for many RA-patients around the world. |
| Alloksys Life Sciences BV (Bunnik, The Netherlands), CEVEC Pharmaceuticals GmbH (Cologne, Germany) and PharmaCell BV (Maastricht, The Netherlands) announce the start of Theraptech, a 2.4 million Euro therapeutic protein development program.... |
| Read more.. |
|
IBET joins ETB Theraptech project |
| IBET (Oeiras, Portugal) joins the Theraptech project. Theraptech aims to develop rec human ALP to be applied in arthritides diseases (e.g. RA and ankylosing spondylitis) as a preferred alternative to current TNFa blockers with a different MOA... |
| Read more.. |
|
New Experimental Medicine in EHEC |
| Bunnik, The Netherlands, June 7, 2011.
Dutch biopharmaceutical company Alloksys Life Sciences has an experimental medicine
which might help to counteract the effects of an EHEC infection.
"We now have over 10 years scientific research ....... |
| Read more.. |
|
Nieuw Experimenteel Medicijn in EHEC |
| Bunnik, 7 juni 2011.
Het Nederlandse biotechnologiebedrijf Alloksys Life Sciences heeft een experimenteel medicijn wat mogelijk kan helpen de gevolgen tegen te gaan van een EHEC-besmetting.
"We hebben inmiddels meer dan 10 jaar wetenschappelijk ....... |
| Read more.. |
|